Abstract: The invention provides a human sigma receptor (SIGR) and polynucleotides which identify and encode SIGR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of SIGR.

Abstract: The present invention provides three human LIM proteins (designated individually as HLIM-1, HLIM-2, and HLIM-3, and collectively as HLIM) and polynucleotides which identify and encode HLIM. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HLIM and a method for producing HLIM. The invention also provides for use of HLIM and agonists, antibodies, or antagonists specifically binding HLIM, in the prevention and treatment of diseases associated with expression of HLIM. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HLIM for the treatment of diseases associated with the expression of HLIM. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HLIM.

Abstract: The present invention provides a human membrane protein (NHMP1) and polynucleotides which identify and encode NHMP1. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHMP1 and a method for producing NHMP1. The invention also provides for agonists, antibodies, or antagonists specifically binding NHMP1, and their use, in the prevention and treatment of diseases associated with expression of NHMP1. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHMP1 for the treatment of diseases associated with the expression of NHMP1. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHMP1.

Abstract: The present invention provides three zinc binding proteins (designated individually as ZB-1, ZB-2, and ZB-3, and collectively as ZB) and polynucleotides which identify and encode ZB. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding ZB and a method for producing ZB. The invention also provides for use of ZB and agonists, antibodies, or antagonists specifically binding ZB, in the prevention and treatment of diseases associated with expression of ZB. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding ZB for the treatment of diseases associated with the expression of ZB. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding ZB.

Abstract: The present invention provides a human tumor-associated Kazal inhibitor (TAKI) and polynucleotides which identify and encode TAKI. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding TAKI and a method for producing TAKI. The invention also provides for agonists, antibodies, or antagonists specifically binding TAKI, and their use, in the prevention and treatment of intestinal diseases including cancer. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding TAKI for the treatment of diseases associated with the expression of TAKI. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding TAKI.

Abstract: The present invention provides polynucleotides which identify and encode two novel human NSP-like proteins (NSPLP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NSPLP. The invention also provides for the use of substantially purified NSPLP, antagonists, and in pharmaceutical compositions for the treatment of diseases associated with the expression of NSPLP. Additionally, the invention provides for the use of antisense molecules to NSPLP in pharmaceutical compositions for treatment of diseases associated with the expression of NSPLP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding NSPLP or anti-NSPLP antibodies which specifically bind to NSPLP.

Abstract: The invention provides a human formin binding protein (FBPhu) and polynucleotides which identify and encode FBPhu. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of FBPhu.

Abstract: The present invention provides a human selenoprotein (HSEL) and polynucleotides which identify and encode HSEL. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSEL and a method for producing HSEL. The invention also provides for agonists, antibodies, or antagonists specifically binding HSEL, and their use, in the prevention and treatment of diseases associated with expression of HSEL. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSEL for the treatment of diseases associated with the expression of HSEL. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HSEL.

Abstract: The present invention provides a human proline-rich acidic protein (PRAP) and polynucleotides which identify and encode PRAP. In addition, the invention provides expression vectors and host cells, agonists, antibodies, or antagonists. This invention also provides methods for preventing or treating disorders associated with the expression of PRAP.

Abstract: The present invention provides a human mitochondrial adenylate kinase (HMAK) and polynucleotides which encode HMAK. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of HMAK.

Abstract: The present invention provides a human pathogenesis-related protein (HPRP) and polynucleotides which identify and encode HPRP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPRP and a method for producing HPRP. The invention also provides for agonists, antibodies, or antagonists specifically binding HPRP, and their use, in the prevention and treatment of diseases associated with expression of HPRP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPRP for the treatment of diseases associated with the expression of HPRP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPRP.

Abstract: The present invention provides polynucleotides encoding stem cell antigens, the partial sequences for which were initially isolated from THP-1 and bladder tumor cDNA libraries and which identify and encode novel human stem cell antigens. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding the stem cell antigens.

Abstract: The present invention provides a novel human chloride channel (HCCP) and polynucleotides which identify and encode HCCP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HCCP and a method for producing HCCP. The invention also provides for agonists, antibodies, or antagonists specifically binding HCCP, and their use, in the prevention and treatment of diseases associated with expression of HCCP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HCCP for the treatment of diseases associated with the expression of HCCP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HCCP.

Abstract: The present invention provides a human histone-like protein (HLP) and polynucleotides which identify and encode HLP. In addition, the invention provides expression vectors and host cells, agonists, antibodies, and antagonists. The invention also provides methods for producing HTP and for treating disorders associated with the expression of HLP.

Abstract: The present invention provides a human 3-hydroxyisobutyryl-coenzyme A hydrolase (HIBCOH) and polynucleotides which identify and encode HIBCOH. The invention also provides expression vectors, host cells, and antibodies. The invention also provides methods for the prevention and treatment of diseases associated with expression of HIBCOH, as well as diagnostic assays.

Abstract: The invention provides two new WD-40 proteins (WDPro) and polynucleotides which identify and encode WDPro. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of WDPro.

Abstract: The present invention provides a human ubiquitin-conjugating enzyme (UBCPB) and polynucleotides which identify and encode UBCPB. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding UBCPB and a method for producing UBCPB. The invention also provides for agonists, antibodies, or antagonists specifically binding UBCPB, and their use, in the prevention and treatment of diseases associated with expression of UBCPB. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding UBCPB for the treatment of diseases associated with the expression of UBCPB. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding UBCPB.

Abstract: The present invention provides nucleic acid and amino acid sequences that identify and encode a novel human map kinase homolog (SMAP) expressed in cells of the human stomach. The present invention also provides for PCR oligomers or hybridization probes for the detection of nucleotide sequences encoding SMAP or SMAP-like molecules, antisense molecules to the nucleotide sequences which encode SMAP, diagnostic tests based on SMAP encoding nucleic acid molecules, genetically engineered expression vectors and host cells for the production of purified SMAP, antibodies capable of binding specifically to SMAP, and agonists and inhibitors with specific binding activity for the polypeptide SMAP.

Abstract: The present invention provides polynucleotides which identify and encode a novel human proteolipid (PLHu). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PLHu. The invention also provides for the use of substantially purified PLHu and its agonists in the commercial production of recombinant proteins for the treatment of diseases associated with the expression of PLHu. Additionally, the invention provides for the use of antisense molecules to PLHu in the treatment of diseases associated with the expression of PLHu. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotides which hybridize with naturally occurring sequences encoding PLHu and antibodies which specifically bind to the protein.

Abstract: The present invention provides a human spermidine/spermine N1-acetyltransferase (S-ACTR) and polynucleotides which identify and encode S-ACTR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding S-ACTR and a method for producing S-ACTR. The invention also provides for use of S-ACTR and agonists, antibodies, or antagonists specifically binding S-ACTR, in the prevention and treatment of cancers. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding S-ACTR for the treatment of diseases associated with the expression of S-ACTR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, or antibodies specifically binding S-ACTR.